Invikafusp Alfa Hits 50% DCR in Solid Tumors
THE FIRST-IN-CLASS, SELECTIVE, dual T-cell agonist invikafusp alfa had a 50% disease-control rate (DCR) in patients with heavily pretreated anti–PD-1/PD-L1–resistant solid tumors, according to findings presented at the 2024 Society for Immunotherapy of …